MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Bladder Cancer · Urinary Bladder Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 45 (planned)
- Started
- Dec 9, 2025
- Main results expected
- Jul 30, 2027
- Fully finished
- Feb 28, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
Measured over: Up to approximately 5 weeks
Number of Participants Who Experience One or More Adverse Events (AEs)
Measured over: Up to approximately 24 months
Number of Participants Who Discontinue Study Treatment Due to AEs
Measured over: Up to approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07222488 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC